All In Biotech

Drug Trial Radar · NCT04221945

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18/ENGOT-cx11/GOG-3047)

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,060 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,060

Actual

Start

May 12, 2020

Primary completion

Jan 7, 2025

Study completion Jan 26, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT)
First posted
Jan 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer. The primary hypotheses are that pembrolizumab plus concurrent chemoradiotherapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free survival and overall survival. Once the study objectives have been met or the study has ended, participants will be discontinued from this study and will be enrolled in an extension study to continue protocol-defined assessments and treatment.

Conditions

  • Uterine Cervical Neoplasms

Interventions

  • PembrolizumabBiological

    IV infusion

  • Placebo for pembrolizumabDrug

    IV infusion

  • CisplatinDrug

    IV infusion

  • External Beam Radiotherapy (EBRT)Radiation

    Given as a total radiotherapy dose of 80 Gy for volume-directed and 75 Gy for point-directed

  • BrachytherapyRadiation

    Given as a total radiotherapy dose of 80 Gy for volume-directed and 75 Gy for point-directed

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the InvestigatorTime frame: Up to approximately 55 months
  2. Overall Survival (OS)Time frame: Up to approximately 55 months

Locations

176 sites in 30 countries. Site status is shown where the registry gives one.

  • HonorHealth Research Institute - Biltmore ( Site 8009)

    Phoenix, Arizona

  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 120) ( Site 0027)

    Los Angeles, California

  • Hoag Memorial Hospital Presbyterian ( Site 0038)

    Newport Beach, California

  • UC Davis Comprehensive Cancer Center ( Site 0017)

    Sacramento, California

  • University of Colorado Health Sciences Center and Hospital ( Site 0028)

    Denver, Colorado

  • Smilow Cancer Center at Yale-New Haven ( Site 0023)

    New Haven, Connecticut

  • AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 0009)

    Orlando, Florida

  • Parkview Research Center at Parkview Regional Medical Center ( Site 0026)

    Fort Wayne, Indiana

  • University of Kentucky Markey Cancer Center ( Site 0015)

    Lexington, Kentucky

  • Our Lady of the Lake Regional Medical Center. ( Site 0031)

    Baton Rouge, Louisiana

  • Women's Cancer Care ( Site 0039)

    Covington, Louisiana

  • Karmanos Cancer Institute ( Site 0018)

    Detroit, Michigan

  • Minnesota Oncology Hematology, PA ( Site 8007)

    Minneapolis, Minnesota

  • University of New Mexico Comprehensive Cancer Center-Clinical Research Office ( Site 0019)

    Albuquerque, New Mexico

  • University of North Carolina at Chapel Hill ( Site 0025)

    Chapel Hill, North Carolina

  • Sanford Bismarck Medical Center ( Site 0046)

    Bismarck, North Dakota

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C

    Columbus, Ohio

  • Willamette Valley Cancer Institute and Research Center ( Site 8000)

    Eugene, Oregon

  • Legacy Good Samaritan Medical Center ( Site 0013)

    Portland, Oregon

  • Allegheny Health Network West Penn Hospital-Gynecologic Oncology ( Site 0030)

    Pittsburgh, Pennsylvania

  • Hollings Cancer Center ( Site 0007)

    Charleston, South Carolina

  • Sanford Gynecology Oncology ( Site 0003)

    Sioux Falls, South Dakota

  • Texas Oncology-Austin Central ( Site 8006)

    Austin, Texas

  • Texas Oncology-Fort Worth Cancer Center ( Site 8001)

    Fort Worth, Texas

  • Texas Oncology-San Antonio Medical Center ( Site 8002)

    San Antonio, Texas

  • Texas Oncology-The Woodlands ( Site 8003)

    The Woodlands, Texas

  • UVA Health System ( Site 0005)

    Charlottesville, Virginia

  • Virginia Commonwealth University ( Site 0024)

    Richmond, Virginia

  • Westmead Hospital ( Site 0973)

    Westmead, New South Wales, Australia

  • Royal Brisbane and Women s Hospital ( Site 0972)

    Herston, Queensland, Australia

  • Monash Health-Monash Medical Centre ( Site 0970)

    Clayton, Victoria, Australia

  • Peter MacCallum Cancer Centre ( Site 0971)

    Melbourne, Victoria, Australia

  • St John of God Subiaco Hospital ( Site 0969)

    Subiaco, Western Australia, Australia

  • Medizinische Universität Wien ( Site 0567)

    Vienna, State of Vienna, Austria

  • Medizinische Universitat Graz ( Site 0569)

    Graz, Styria, Austria

  • Medizinische Universitat Innsbruck ( Site 0566)

    Innsbruck, Tyrol, Austria

  • UZA University Hospital Antwerp ( Site 0351)

    Edegem, Antwerpen, Belgium

  • GZA Sint Augustinus ( Site 0356)

    Wilrijk, Antwerpen, Belgium

  • C.I.U. Hopital Ambroise Pare ( Site 0353)

    Mons, Hainaut, Belgium

  • OLV Ziekenhuis ( Site 0352)

    Aalst, Oost-Vlaanderen, Belgium

Showing 40 of 176 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.